Debiopharm
Corporate brand
UnclaimedA privately held Swiss biopharmaceutical group that develops, clinically tests, manufactures and licenses medicines, with a historic concentration on oncology and infectious diseases.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Debiopharm is a privately held Swiss biopharmaceutical group whose principal activity is the development of drug candidates and the preparation of those candidates for licensing and commercialization by larger pharmaceutical partners. Founded in Martigny in 1979 by Rolland-Yves Mauvernay, the company has built its business around acquiring or in-licensing promising molecules, advancing them through preclinical and clinical development, and transferring successful products to commercial partners rather than maintaining a conventional large-scale sales organization of its own. The company’s best-known development achievements are triptorelin and oxaliplatin. Debiopharm began working on interferon and related biological research during its early years, then acquired development rights to triptorelin from Tulane University in 1982. Triptorelin is a gonadotropin-releasing hormone agonist used in several indications, including advanced prostate cancer and endometriosis. Its first marketing authorization was obtained in France in 1986, and the product has subsequently been commercialized in different markets under names including Decapeptyl, Pamorelin and Trelstar. In 1989, Debiopharm licensed oxaliplatin from Nagoya City University. The platinum-based medicine was approved in Europe in 1996 and became an important treatment for metastatic colorectal cancer, later being used in other gastrointestinal cancers. Both medicines are associated with the company’s historical growth and are included on the World Health Organization’s Model List of Essential Medicines. Debiopharm’s operating model is partnership-led. Its development organization seeks external molecules, technologies and scientific collaborations, supports laboratory and clinical work, and then licenses assets to companies capable of conducting global commercialization. Examples of research or development relationships described publicly include collaborations with MSM Protein Technologies in oncology, Yale University in autoimmune and inflammatory diseases, Evotec in oncology discovery, and Nobelex Biotech in antibiotic research. In 2005, the group acquired Canadian company H3 Pharma and renamed it Debiovision to support medicine development and worldwide registration activities. The group includes Debiopharm International, which in-licenses and develops drug candidates; Debiopharm Research & Manufacturing, based in Martigny and focused on pharmaceutical research, development and manufacturing; and Debiopharm Innovation Fund, which invests in digital-health and related life-science companies. The manufacturing site is Swissmedic-certified and was renovated and expanded in 2015. The innovation fund has reported investments in companies such as Carevive, VivoSense and Iktos, and an investment in Kaiku Health was exited after its acquisition by Elekta. Debiopharm remains active in oncology, infectious diseases, radiopharmaceuticals and selected specialty-medicine areas. Its pipeline has included xevinapant for head and neck cancer, afabicin for staphylococcal infections, zedoresertib for glioblastoma, antibody-drug-conjugate research, sustained-release somatostatin therapy and a gonadotropin-releasing hormone program. In 2021, Merck KGaA obtained an exclusive license to the xevinapant program for an announced potential consideration of up to EUR 900 million; Merck later discontinued the project in 2024. In 2024, ITM Isotope Technologies Munich announced an exclusive global license for the development and commercialization of Debiopharm’s peptide-based radiopharmaceutical theranostic pair, then identified as ITM-91 and ITM-94D. Debiopharm operates from sites in Lausanne and Martigny and remains part of the privately held Après-demain group.
History
Rolland-Yves Mauvernay established Debiopharm in Martigny, Switzerland, in 1979. The group initially pursued work involving interferon and related biological research. In 1981, it created the Cytotech laboratory, which later developed into Debio Recherche Pharmaceutique and subsequently Debiopharm Research & Manufacturing. This research and manufacturing capability became a lasting part of the company’s vertically integrated development model. A decisive early step came in 1982, when Debiopharm obtained rights from Tulane University to develop triptorelin. The molecule is a gonadotropin-releasing hormone agonist with applications including prostate cancer and endometriosis. Debiopharm secured its first marketing authorization for triptorelin in France in 1986. The product was later marketed internationally under several brand names and became one of the company’s central commercial and scientific achievements. In 1989, Debiopharm acquired a license for oxaliplatin from Nagoya City University. European approval followed in 1996. Oxaliplatin subsequently became an established component of treatment for metastatic colorectal cancer and was also used in other gastrointestinal cancers. Together, triptorelin and oxaliplatin established Debiopharm’s reputation as a specialist developer able to advance important medicines and then work with other pharmaceutical companies on broad commercialization. The company later consolidated its presence in Lausanne. From 2004, its headquarters operated from the building known as Après-demain Forum, a property associated with architect Jean Tschumi and recognized as a cultural property of national significance. In 2005, Debiopharm acquired Canadian company H3 Pharma and renamed it Debiovision. The acquisition supported development and worldwide registration activities for the group’s medicines. Rather than relying exclusively on an internal discovery engine, Debiopharm developed a partnership-based strategy. Publicly described collaborations include a 2009 oncology project with MSM Protein Technologies, a 2011 agreement with Yale University relating to autoimmune and inflammatory diseases, a 2014 collaboration with Evotec to identify and develop cancer compounds, and a 2014 relationship with Nobelex Biotech focused on antibiotics targeting Neisseria gonorrhoeae and enteric species. This approach allowed the company to combine external science, internal development capabilities and later licensing transactions. The group’s structure came to include Debiopharm International for drug development and licensing, Debiopharm Research & Manufacturing for research and production, and Debiopharm Innovation Fund for venture investments in digital health and related technologies. The Martigny production facility was renovated and expanded in 2015 and is Swissmedic-certified. The innovation fund reported investments in Carevive in 2020, VivoSense in 2022 and Iktos in 2023. Its investment in Kaiku Health ended in an exit when Elekta acquired the Finnish oncology-software company in 2020. Asset-management activities formerly handled by Debiopharm Investment SA were transferred to the holding company after a merger completed by 2020. Debiopharm continued to expand its partnering model through its oncology and radiopharmaceutical pipeline. In 2021, Merck KGaA obtained an exclusive license for xevinapant, an oral inhibitor-of-apoptosis-protein program for locally advanced squamous-cell carcinoma of the head and neck. Merck discontinued the project in 2024. In September 2024, ITM Isotope Technologies Munich announced an exclusive global license for the development and commercialization of Debiopharm’s peptide-based radiopharmaceutical theranostic pair, linking the company’s development activities with a specialist radiopharmaceutical platform. Debiopharm currently maintains operations in Lausanne and Martigny and remains the life-science division of the privately held Après-demain group.
- 2024
Radiopharmaceutical program is licensed to ITM
[1]ITM Isotope Technologies Munich announces an exclusive global license for Debiopharm’s peptide-based theranostic pair.
- 2021
Xevinapant is licensed to Merck KGaA
[1]Merck KGaA obtains an exclusive license for the xevinapant oncology program.
- 2015
Martigny manufacturing site is expanded
[1]The Swissmedic-certified Debiopharm Research & Manufacturing facility is renovated and expanded.
- 2005
H3 Pharma is acquired
[1]Debiopharm acquires the Canadian company H3 Pharma and rebrands it Debiovision.
- 2004
Headquarters move to Lausanne
[1]Debiopharm moves its headquarters to the building later known as Après-demain Forum.
- 1996
Oxaliplatin receives European approval
[1]Oxaliplatin is approved in Europe and later becomes an established colorectal-cancer treatment.
- 1989
Oxaliplatin is licensed
[1]Debiopharm acquires a license for oxaliplatin from Nagoya City University.
- 1986
First triptorelin marketing authorization
[1]The first marketing authorization for triptorelin is obtained in France.
- 1982
Triptorelin development rights are acquired
[1]Debiopharm obtains development rights to triptorelin from Tulane University.
- 1981
Cytotech laboratory is created
[1]The laboratory that later became Debiopharm Research & Manufacturing is established.
Products and positioning
A partnership-oriented Swiss drug developer that specializes in translating externally sourced or internally identified candidates into clinically validated medicines and licensing them to global commercialization partners, with particular expertise in oncology and infectious diseases.
Hormonal oncology and reproductive-health medicine · 1986
Triptorelin
Triptorelin is a gonadotropin-releasing hormone agonist originally developed by Debiopharm after the company acquired development rights from Tulane University. It has been approved for indications including advanced prostate cancer and endometriosis and has been marketed in different territories under names such as Decapeptyl, Neo Decapeptyl, Pamorelin and Trelstar. Other market-specific uses and brand names have also been reported.
Oncology medicine · 1996
Oxaliplatin
Oxaliplatin is a diaminocyclohexane platinum compound licensed by Debiopharm from Nagoya City University in 1989. After European approval in 1996, it became an established treatment for metastatic colorectal cancer and has also been used in gastric and liver cancers. Depending on territory and commercial partner, it has appeared under names including Eloxatin, Elplat, Dacotin and Dacplat.
Oncology development program
Xevinapant
Xevinapant is an orally available inhibitor of apoptosis proteins investigated for high-risk patients with locally advanced squamous-cell carcinoma of the head and neck. Debiopharm licensed the program exclusively to Merck KGaA in 2021. Merck later discontinued the project in 2024.
Antibiotic development program
Afabicin
Afabicin is an enoyl-acyl carrier protein reductase inhibitor designed as an antistaphylococcal antibiotic. The program was directed toward acute bacterial skin and skin-structure infections and reflects Debiopharm’s continuing interest in anti-infective development.
Oncology development program
Zedoresertib (Debio 0123)
Zedoresertib, also identified as Debio 0123, is a WEE1 inhibitor being investigated in oncology, including potential applications in glioblastoma.
Radiopharmaceutical theranostic program
Debio 0228 / ITM-94D
Debio 0228 is a peptide-based program targeting the CAIX enzyme and was developed with 3B Pharmaceuticals. In 2024, ITM Isotope Technologies Munich obtained an exclusive global license covering the related theranostic pair identified as ITM-91 and ITM-94D, also associated with Debiopharm codes Debio 0328 and Debio 0228.
Oncology development program
Lunresertib (Debio 2513)
Lunresertib, or Debio 2513, is a PKMYT1 inhibitor designed to exploit genetic vulnerabilities in solid tumors, including tumors with CCNE1 amplification.
Antibody-drug conjugate research program
Debio 1562M
Debio 1562M is described as a second-generation antibody-drug conjugate directed against CD37 and incorporating Multilink cleavable linker-payload technology. The preclinical program has been associated with blood-cancer areas including acute myeloid leukemia and myelodysplastic syndromes.
Endocrinology development program
Debio 4126
Debio 4126 is a sustained-release formulation of a somatostatin analogue intended for investigation in acromegaly.
Hormonal development program
Debio 4326
Debio 4326 is a gonadotropin-releasing hormone agonist program intended for investigation in central precocious puberty.
Brand decisions
2024
License radiopharmaceutical theranostic program to ITMM&ABackground
Debiopharm’s peptide-based CAIX-targeting radiopharmaceutical program required a specialist partner for clinical and commercial development.
Action taken
ITM Isotope Technologies Munich received an exclusive global license for the clinical and commercial development of the ITM-91 and ITM-94D pair.
Aftermath
The transaction transferred further development and commercialization responsibility to ITM.
2021
License xevinapant to Merck KGaAM&ABackground
Debiopharm’s xevinapant program had generated clinical evidence in locally advanced head and neck cancer and required a global development and commercialization partner.
Action taken
Debiopharm granted Merck KGaA an exclusive license for further development and commercialization.
Aftermath
Merck discontinued the project in 2024.
Announced potential license value. EUR 900 million (2021 announcement)
2005
Acquire and rebrand H3 PharmaM&ABackground
Debiopharm sought additional support for the development and worldwide registration of its medicines.
Action taken
The group acquired Canadian company H3 Pharma and renamed it Debiovision.
Aftermath
Debiovision became part of Debiopharm’s international development and registration structure.
Recent events
Reported
Debiopharm unveils pre-clinical results for MultiLINK ADC linker technologies at World ADC 2026[3]
Swiss-based biopharmaceutical company Debiopharm announced pre-clinical proof-of-concept research on its MultiLINK Linker Technology suite (MLINK Select, MLINK Duo, MLINK HiSol), presented at World ADC 2026 in San Diego. Results showed broadening of the therapeutic index for vedotin-based ADCs with MLINK Select, synergistic antitumor activity for dual-payload MLINK Duo ADCs, and MLINK HiSol's potential to enable targeted small-molecule inhibitor payloads.
Reported
Oncomfort completes €10 million Series A funding round[4]
Oncomfort announced the completion of a €10 million Series A funding round co-led by Debiopharm and Crédit Mutuel Innovation. The company said it planned to use the investment to develop its digital therapy solutions and accelerate international expansion.
Reported
Novadiscovery closes first €5 million of Series A funding[5]
Novadiscovery closed the first €5 million of a planned €7 million Series A funding round, with Debiopharm leading the investment.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/debiopharm · Editorial policy · How profiles are compiled